Anicetti Vincent R 4
4 · Coherus BioSciences, Inc. · Filed Feb 19, 2021
Insider Transaction Report
Form 4
Anicetti Vincent R
Chief, Quality & Compliance
Transactions
- Exercise/Conversion
Common Stock
2021-02-17$2.50/sh+2,488$6,221→ 62,227 total - Sale
Common Stock
2021-02-17$17.45/sh−2,488$43,418→ 59,739 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-02-17−2,488→ 0 totalExercise: $2.50Exp: 2024-06-30→ Common Stock (2,488 underlying)
Footnotes (4)
- [F1]Includes 52,083 restricted stock units.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.
- [F3]The transaction was executed in multiple trades in prices ranging from $17.19 to $17.64, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- [F4]All of the shares underlying this option are vested and exercisable as of the date hereof.